Results 141 to 150 of about 14,831 (254)

Protective Role for Itaconate During Inhaled Allergen Challenge

open access: yesAllergy, Volume 81, Issue 4, Page 1099-1110, April 2026.
Itaconate levels decrease in sputum following allergen inhalation in mild asthmatics, suggesting a dynamic metabolic response to airway challenge. Genetic deletion of Acod1 in mice did not alter airway inflammation or remodelling in response to chronic HDM exposure.
Gesa J. Albers   +16 more
wiley   +1 more source

Systemic corticosteroids for acute otitis media in children [PDF]

open access: yes, 2016
Beller, Elaine M.   +6 more
core   +1 more source

The Therapeutic Potential of Farm Dust Extracts in a Mouse Model of Eosinophilic Inflammation

open access: yesAllergy, Volume 81, Issue 4, Page 1173-1192, April 2026.
Farm dust extract (FDE) treatment reduces airway eosinophilia, mucus overproduction, and MHC‐II expression on DCs, limiting antigen presentation and Th2 inflammation. It increases PD‐L1 on DCs, promoting T cell deactivation. Additionally, FDE enhances Tregs and upregulates CTLA‐4, reinforcing suppression.
Rabia Ülkü Korkmaz   +16 more
wiley   +1 more source

Clinical effects of intranasal corticosteroids on nasal symptoms in subjects with chronic rhinitis during COVID-19. [PDF]

open access: yesAllergy Asthma Proc, 2022
Tuzer C   +12 more
europepmc   +1 more source

Allergic Rhinitis and Its Impact on Asthma (ARIA)‐EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments

open access: yesAllergy, Volume 81, Issue 4, Page 954-976, April 2026.
ABSTRACT Background Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI‐endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024 ...
Bernardo Sousa‐Pinto   +252 more
wiley   +1 more source

Long‐Term Effect of Allergen Immunotherapy in Responder Local Allergic Rhinitis Patients: Symptom Control, and Prevention of Asthma and Allergic Sensitizations

open access: yesAllergy, Volume 81, Issue 4, Page 1124-1137, April 2026.
LAR patients who respond to AIT during the first year and are treated for two more years continue improving (less symptoms and medication intake) during the following seven years. AIT prevents the onset of asthma and allergic sensitizations in responder LAR individuals during the seven years following discontinuation.
Almudena Testera‐Montes   +9 more
wiley   +1 more source

Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases

open access: yesJournal of Asthma and Allergy, 2017
Pete Smith,1 David Price,2,3 Richard Harvey,4,5 Andrew Simon Carney,6 Vicky Kritikos,7 Sinthia Z Bosnic-Anticevich,7,8 Louise Christian,9 Derek Skinner,10 Victoria Carter,10 Alice Marie Sybille Durieux3 1Clinical Medicine, Griffith University, Southport,
Smith P   +9 more
doaj  

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

open access: yesAllergy, Volume 81, Issue 4, Page 1000-1023, April 2026.
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Sanna Toppila‐Salmi   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy